These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 34515596

  • 1. A Taiwanese study on real-world evidence with vortioxetine in patients with major depression in Asia (TREVIDA).
    Yang YK, Chen CS, Tsai CF, Chang CM, Lai TJ, Lee CT, Lin CC, Lan TH, Herr KJ.
    Curr Med Res Opin; 2021 Dec; 37(12):2163-2173. PubMed ID: 34515596
    [Abstract] [Full Text] [Related]

  • 2. A comparison of real-world effectiveness of vortioxetine along the treatment algorithm for major depressive disorder.
    Bose R, Hamdani SU, Minhas FA, Herr KJ.
    Curr Med Res Opin; 2022 May; 38(5):661-671. PubMed ID: 35049384
    [Abstract] [Full Text] [Related]

  • 3. Results of a real-world study on vortioxetine in patients with major depressive disorder in South East Asia (REVIDA).
    Chin CN, Zain A, Hemrungrojn S, Ung EK, Kwansanit P, Au Yong KC, Chong MSW, Inpa C, Yen TH, Yeoh BBD, Tay LK, Bernardo C, Lim LC, Yap CH, Fones C, Nayak A, Nelleman L.
    Curr Med Res Opin; 2018 Nov; 34(11):1975-1984. PubMed ID: 29768955
    [Abstract] [Full Text] [Related]

  • 4. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study.
    Chokka P, Bougie J, Proulx J, Tvistholm AH, Ettrup A.
    CNS Spectr; 2019 Dec; 24(6):616-627. PubMed ID: 30802419
    [Abstract] [Full Text] [Related]

  • 5. Safety and effectiveness of vortioxetine in patients with major depressive disorder in a real-life clinical setting in India: results from an interventional, flexible-dose study.
    Adair M, Bose R, Schmidt SN.
    Curr Med Res Opin; 2024 Sep; 40(9):1637-1645. PubMed ID: 39110846
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness of vortioxetine in elderly patients with major depressive disorder in real-world clinical practice: Results from the RELIEVE study.
    Di Nicola M, Adair M, Rieckmann A, Christensen M C.
    J Psychopharmacol; 2024 Jul; 38(7):615-623. PubMed ID: 39077889
    [Abstract] [Full Text] [Related]

  • 7. Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD).
    Chokka P, Bougie J, Rampakakis E, Proulx J.
    CNS Spectr; 2019 Jun; 24(3):338-347. PubMed ID: 29792585
    [Abstract] [Full Text] [Related]

  • 8. Real-world clinical outcomes and treatment patterns in patients with MDD treated with vortioxetine: a retrospective study.
    McDaniel BT, Cornet V, Carroll J, Chrones L, Chudzik J, Cochran J, Guha S, Lawrence DF, McCue M, Sarkey S, Lorenz B, Fawver J.
    BMC Psychiatry; 2023 Dec 13; 23(1):938. PubMed ID: 38093196
    [Abstract] [Full Text] [Related]

  • 9. Effectiveness of vortioxetine in patients with major depressive disorder and co-morbid generalized anxiety disorder in routine clinical practice: A subgroup analysis of the RELIEVE study.
    Almeida SS, Christensen MC, Simonsen K, Adair M.
    J Psychopharmacol; 2023 Mar 13; 37(3):279-288. PubMed ID: 36377523
    [Abstract] [Full Text] [Related]

  • 10. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
    Mahableshwarkar AR, Jacobsen PL, Chen Y.
    Curr Med Res Opin; 2013 Mar 13; 29(3):217-26. PubMed ID: 23252878
    [Abstract] [Full Text] [Related]

  • 11. Canadian economic impact of improved workplace productivity in patients with major depressive disorder treated with vortioxetine.
    Lachaine J, Beauchemin C, Bibeau J, Patenaude J, Chokka P, Proulx J, Bougie J.
    CNS Spectr; 2020 Jun 13; 25(3):372-379. PubMed ID: 31120009
    [Abstract] [Full Text] [Related]

  • 12. Effect of vortioxetine in subjects with major depressive and alcohol use disorders: a 6-month retrospective analysis.
    Di Nicola M, Pepe M, Panaccione I, Moccia L, Dattoli L, Molinaro M, Sani G, Janiri L, McIntyre RS.
    CNS Spectr; 2022 Feb 13; 27(1):73-81. PubMed ID: 32772956
    [Abstract] [Full Text] [Related]

  • 13. Real-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects.
    Papalexi E, Galanopoulos A, Kontis D, Markopoulou M, Balta G, Karavelas E, Panagiotidis P, Vlachos T, Ettrup A.
    BMC Psychiatry; 2022 Aug 12; 22(1):548. PubMed ID: 35962369
    [Abstract] [Full Text] [Related]

  • 14. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study.
    Baune BT, Sluth LB, Olsen CK.
    J Affect Disord; 2018 Mar 15; 229():421-428. PubMed ID: 29331703
    [Abstract] [Full Text] [Related]

  • 15. Effectiveness and Safety of Vortioxetine for the Treatment of Major Depressive Disorder in the Real World: A Systematic Review and Meta-Analysis.
    Li Z, Liu S, Wu Q, Li J, Yang Q, Wang X, Peng P, Wang Q, Liu Y, Li M, Hao Y, Xu H, He L, Wang Y, Chen S, Liu T.
    Int J Neuropsychopharmacol; 2023 Jun 23; 26(6):373-384. PubMed ID: 37105713
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness of vortioxetine in patients with major depressive disorder and early-stage dementia: The MEMORY study.
    Christensen MC, Schmidt SN, Grande I.
    J Affect Disord; 2023 Oct 01; 338():423-431. PubMed ID: 37315590
    [Abstract] [Full Text] [Related]

  • 17. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder.
    Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RS.
    Neuropsychopharmacology; 2015 Jul 01; 40(8):2025-37. PubMed ID: 25687662
    [Abstract] [Full Text] [Related]

  • 18. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
    Jacobsen PL, Harper L, Chrones L, Chan S, Mahableshwarkar AR.
    Int Clin Psychopharmacol; 2015 Sep 01; 30(5):255-64. PubMed ID: 26020712
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness of Vortioxetine in Patients with Major Depressive Disorder in Real-World Clinical Practice: French Cohort Results from the Global RELIEVE Study.
    Polosan M, Rabbani M, Christensen MC, Simonsen K, Ren H.
    Neuropsychiatr Dis Treat; 2022 Sep 01; 18():1963-1974. PubMed ID: 36068858
    [Abstract] [Full Text] [Related]

  • 20. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.
    Li G, Wang X, Ma D.
    Clin Drug Investig; 2016 Jul 01; 36(7):509-17. PubMed ID: 27067232
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.